Subsidiary Sharp FMSG obtaining Sharp Life shares

Subject:Subsidiary Sharp FMSG Life Science Company KY obtaining Sharp Life Science (EU) Limited shares

Date of events:2019/09/25

Contents:

1.Name and nature of the subject matter (if preferred shares, the terms and conditions of issuance shall also be indicated, e.g.dividend yield):

Sharp Life Science (EU) Limited common shares

2.Date of occurrence of the event:2019/02/27~2019/09/25

3.Volume, unit price, and total monetary amount of the transaction:

16,000 shares at about GBP 500 each;Total amount equals GBP 8,000,000

4.Counterparty to the trade and its relationship to the Company (if the trading counterpart is a natural person and furthermore is not an actual related party of the Company, the name of the trading counterpart is not required to be disclosed):

Capital Increased by Cash is not applied;Parent and subsidiary companies

5.Where the counterpart to the trade is an actual related party, a public announcement shall also be made of the reason for choosing the related party as trading counterpart and the identity of the previous owner (including its relationship with the company and the trading counterpart), price of transfer, and date of acquisition:

Increase by cash in subsidiary's capital;Na

6.The manner in which the current transaction was decided, the reference basis for the decision on price, and the decision-making department:Board of Directors

7.Current cumulative volume, amount, and shareholding percentag of holdings of the security being traded (including the current trade) and status of any restriction of rights (e.g.pledges):

54,861 shares;GBP 27,430,500;approximately 83.34%;

restriction of rights:None

8.Current ratio of long or short term securities investment (including the current trade) to the total assets and shareholder's equity as shown in the most recent financial statement and the operating capital as shown in the most recent financial statement:

Ratio to total assets:0.0382%, ratio to shareholder's equity:0.0968%

Operating Capital:NTD-28,636,429,000

9.Concrete purpose or use of the acquisition or disposal:

Long Term Investment

10.Is it a related party transaction?:Yes

11.Date of the board of directors'resolution:2019/09/25

12.Name of the CPA firm:ATAX Accounting Firm

13.Name of the certifying CPA:Danny Cheng

14.The practice certificate number of the CPA:

Financial-Supervisory-Securities-Corporate-5720